MRK Stock Recent News

The U.S. FDA on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's portfolio

The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

Medtronic and Merck are innovative healthcare leaders. Both are developing new products to keep sales growing.

Merck (MRK) concluded the recent trading session at $123.85, signifying a +1.35% move from its prior day's close.

Merck said on Friday its drug Keytruda, in combination with chemoradiotherapy, met the main goal in a late-stage study in newly diagnosed patients with high-risk locally advanced cervical cancer.

Merck (MRK) concluded the recent trading session at $120.51, signifying a -1.35% move from its prior day's close.

Merck (MRK) concluded the recent trading session at $122.16, signifying a -0.41% move from its prior day's close.

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Merck & Co said on Wednesday it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the efficacy and safety of a single-dose regimen compared to the approved three-dose regimen.